A randomised dose finding study of oral tacrolimus (FK506) therapy in refractory ulcerative colitis

2006458 citationsJournal Articlebronze Open Access

Authors

Hisao Ogata · Keio University

T Matsui · Fukuoka University

M Nakamura · Jikei University Kashiwa hospital

M Iida · Kyushu University

M Takazoe · Tokyo Yamate Medical Center

Y Suzuki · Chiba University Hospital

T Hibi · Keio University Hospital

Abstract

Our findings demonstrate dose dependent efficacy and safety of oral tacrolimus for remission-induction therapy of refractory UC. The optimal target range appears to be 10-15 ng/ml in terms of efficacy with two week therapy.

Topics & Keywords

Inflammatory Bowel Disease Mycobacterium research and diagnosis Cholangiocarcinoma and Gallbladder Cancer Studies

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Gut

Volume 55, Issue 9, pp. 1255-1262

DOI: 10.1136/gut.2005.081794

Field-Weighted Citation Impact: 14.34